Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinumtoxin A for Myogenous TMD
NCT06941636Phase 3Recruiting
- Sponsor
- Region Stockholm
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A in temporomandibular disorders (TMD) (2 arms), sponsored by Region Stockholm. Primary endpoint: Changes in pain and impact of doses on pain relief at 6 months. Started May 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
temporomandibular disorders (TMD)
Beyond the preview
Go deeper on NCT06941636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941636.